The Probability of Tiered Benefit: Partial Identification with Robust and Stable Inference
分层获益概率:部分识别与稳健、稳定的推断AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要直接研究反事实获益概率的部分识别,并针对有序结局及连续结局的分层变化。
分层获益概率:部分识别与稳健、稳定的推断AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
We define the Probability of Tiered Benefit in scenarios with a binary exposure and an outcome that is either categorical with $K \geq 2$ ordered tiers or continuous partitioned by $K-1$ fixed thresholds into disjoint intervals. Similarly to other pure counterfactual queries, this parameter is not $g$-identifiable without additional assumptions. We demonstrate that strong monotonicity does not suffice for point identification when $K \geq 3$ and provide sharp bounds both with and without such constraint. Inference and uncertainty quantification for these bounds are challenging tasks due to potential nonregularity induced by ambiguities in the underlying individualized optimization problems. Such ambiguities can arise from immunities or null treatment effects in subpopulations with positive probability, affecting the lower bound estimate and hindering conservative inference. To address these issues, we extend the available Stabilized One-Step Correction (S1S) procedure by incorporating stratum-specific stabilizing matrices. Through simulations, we illustrate the benefits of this approach over existing alternatives. We apply our method to estimate bounds on the probabilities of tiered benefit and harm from pharmacological treatment for ADHD upon academic achievement, employing observational data from diagnosed Norwegian schoolchildren. Our findings indicate that while girls and children with low prior test performance could have moderate chances of both benefit and harm from treatment, a clear-cut recommendation remains uncertain across all strata.